Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03673124 · OUTCOME

Mutation Analysis of Genomic Signatures

Ribociclib and Letrozole Treatment in Ovarian Cancer · Source last updated 2025-12-23

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
At time of primary and secondary outcome analysis up to 5 years

What was measured

Determine genomic signatures associated with response and clinical benefit of the combination of letrozole + Ribociclib

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
Determine genomic signatures associated with response and clinical benefit of the combination of letrozole + Ribociclib
reporting Status
NOT_POSTED
time Frame
At time of primary and secondary outcome analysis up to 5 years
title
Mutation Analysis of Genomic Signatures
type
OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice